Cosentyx

Cosentyx

secukinumab

Manufacturer:

Novartis

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Secukinumab
Indications/Uses
Adults w/ moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy; axial spondyloarthritis w/ or w/o radiographic damage; active ankylosing spondylitis (AS) or axial spondyloarthritis w/ radiographic damage; & active non-radiographic axial spondyloarthritis or axial spondyloarthritis w/ objective signs of inflammation. As monotherapy or in combination w/ methotrexate for active psoriatic arthritis in adults.
Dosage/Direction for Use
SC Plaque psoriasis 300 mg (as two 150 mg inj) w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance. Psoriatic arthritis 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing. May be increased to 300 mg. Patients who are anti-TNFα inadequate responders or w/ concomitant moderate to severe plaque psoriasis 300 mg (as two 150 mg inj) w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing. Each 300 mg dose is given as 2 SC inj of 150 mg. Axial spondyloarthritis, AS 150 mg w/ initial dosing at wk 0, 1, 2, 3, & 4 followed by mthly maintenance dosing. May be increased to 300 mg (given as two 150 mg inj). Non-radiographic axial spondyloarthritis 150 mg w/ initial dosing at wk 0, 1, 2, 3 & 4 followed by mthly maintenance dosing.
Contraindications
Severe hypersensitivity reactions.
Special Precautions
Discontinue immediately & initiate appropriate therapy if anaphylactic or other serious allergic reaction occurs. May increase risk of infections. Patients w/ chronic or history of recurrent infection; active inflammatory bowel disease (eg, Crohn's disease & ulcerative colitis). Closely monitor patients w/ active inflammatory bowel disease if serious infection develops & do not administer until infection resolves. Do not give to patients w/ active TB. Consider anti-TB therapy prior to initiation in patients w/ latent TB. Should not be given concurrently w/ live vaccines. Caution should be exercised during pregnancy & lactation. Ped <18 yr.
Adverse Reactions
Upper resp tract infection (nasopharyngitis, rhinitis). Oral herpes; rhinorrhea; diarrhea; urticaria.
Drug Interactions
Not to be given concurrently w/ live vaccines.
MIMS Class
Disease-Modifying Anti-Rheumatic Drugs (DMARDs) / Immunosuppressants / Psoriasis, Seborrhea & Ichthyosis Preparations
ATC Classification
L04AC10 - secukinumab ; Belongs to the class of interleukin inhibitors. Used as immunosuppressants.
Presentation/Packing
Form
Cosentyx soln for inj 150 mg/mL
Packing/Price
1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in